Why is ALNEV.PA stock falling today?

ALNEV.PA stock is down due to heavy selling on a tiny market cap, recent lack of earnings updates, and continued cash burn. Volume at **7,738,367** amplifies percentage moves for this low-price biotech.

What are the main risks for ALNEV.PA stock investors?

Main risks are funding needs, ongoing negative operating cash flow (**EUR -20.64** per share), thin liquidity, and binary trial outcomes for Kinoid programs that can swing value sharply.

Does Meyka AI provide a price forecast for ALNEV.PA stock?

Meyka AI's forecast model projects a monthly change of **EUR -0.17** and issues scenario targets (short **EUR 0.005**, conservative **EUR 0.020**, downside **EUR 0.001**). Forecasts are projections and not guarantees.

How does ALNEV.PA stock compare with the Healthcare sector?

ALNEV.PA stock lags the Healthcare sector; it has lower liquidity and a current ratio **0.63** versus sector average **~2.15**, reflecting weaker short-term financial resilience.

EU Stocks

ALNEV.PA Neovacs S.A. pre-market down 6.25% to EUR 0.003 on 06 Feb 2026: monitor catalysts

ByDanny Kontos February 6, 2026February 6, 2026

We see ALNEV.PA stock trading down 6.25% in pre-market on 06 Feb 2026, at EUR 0.003 with 7,738,367 shares changing hands. This move follows heavy intraday volume and persistent downward pressure since the company’s valuation compressed to a market cap near EUR 1,335. We summarise why Neovacs S.A. (ALNEV.PA) is among the top losers this session, connect clinical and cash signals to price action, and outline short-term trading risks and potential catalysts for Europe-listed investors.